Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,665 across all filing types
Latest filing 2017-11-01 Regulatory Filings
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
AHZ RESPONDS TO MEDIA SPECULATION 2 pages 169.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 2 November 2017 from Admedus Limited addressing media speculation about funding and strategic options related to its subsidiary, Admedus Vaccines Pty Ltd and Admedus Immunotherapies. It references a prior announcement of FY2017 financial results but does not contain any financial statements or detailed financial data itself. The content is a corporate update clarifying the company's position and compliance with continuous disclosure rules. The document length is short (2361 characters) and it serves as a communication or regulatory announcement rather than a full financial report or detailed presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for general regulatory announcements and compliance documents that do not fit other specific categories.
2017-11-01 English
Appendix 4C - quarterly 7 pages 217.8KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Admedus Limited Quarterly report - Appendix 4C for period to 30 September 2017' and contains detailed quarterly financial information including cash flow statements, operational highlights, and financing updates. It references the ASX Listing Rule 4.7B, which mandates quarterly reporting. The content includes actual financial data for the quarter ended 30 September 2017, such as cash flows from operating, investing, and financing activities, as well as narrative on sales and business developments during the quarter. The document is approximately 14,478 characters long, indicating it is a full report rather than a brief announcement. The presence of detailed financial statements and analysis confirms it is a comprehensive interim/quarterly report. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2018
2017-10-30 English
Admedus announces facility agreement with PFG 2 pages 373.4KB
Capital/Financing Update Classification · 95% confidence The document is an announcement dated 26 October 2017 from Admedus Limited regarding entering into a secured debt facility agreement with Partners for Growth. It details the terms of the loan facility, interest rates, repayment period, security, and warrants issued. There is no financial statement or comprehensive financial report included. The document is focused on financing activity and capital structure changes. The length is 3379 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document fits the category of Capital/Financing Update (CAP).
2017-10-25 English
Appendix 3B 14 pages 785.5KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form, which is a standard Australian Securities Exchange (ASX) form used for announcements related to new issues of securities, applications for quotation of additional securities, and related agreements. It details the class and number of securities issued, terms of the securities, issue price, purpose, and compliance with ASX listing rules. The document is not a financial report, earnings release, or management discussion but rather a regulatory announcement about capital raising and securities issuance. This fits the definition of a Capital/Financing Update (CAP) filing, as it provides updates on company fundraising and capital structure changes.
2017-10-25 English
Notice under Section 708(A)(e) of the Corporations Act 1
Capital/Financing Update Classification · 95% confidence The document is a notice under section 708A(5) of the Corporations Act 2001 regarding the issue of a warrant by Admedus Limited. It provides legal compliance statements about the warrant issuance and references the Corporations Act. The document is short (1377 characters) and serves as a formal announcement of a capital raising instrument (warrant) issued without disclosure under certain provisions. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. It is not a full financial report or audit, nor a regulatory filing or announcement of a report publication. Therefore, the correct classification is CAP with high confidence.
2017-10-25 English
Admedus TAVR project on track with new IP application 2 pages 273.0KB
Capital/Financing Update Classification · 95% confidence The document is a news release dated 24 October 2017 from Admedus Limited announcing the submission of new intellectual property (IP) applications related to a Transcatheter Aortic Valve Replacement (TAVR) device. It discusses the company's product development, market entry, and technological innovations. There are no financial statements, regulatory certifications, voting results, or management changes. The content is an update on company activities related to capitalizing on new IP and product development, which aligns with a Capital/Financing Update. The document is not a full financial report, earnings release, or regulatory filing, but rather an announcement of strategic business progress and IP filings, which fits best under Capital/Financing Update (CAP).
2017-10-23 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.